Alimera Sciences (ALIM)
(Delayed Data from NSDQ)
$5.59 USD
+0.02 (0.36%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $5.58 -0.01 (-0.18%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum B VGM
Brokerage Reports
0 items in cart
Alimera Sciences, Inc. [ALIM]
Reports for Purchase
Showing records 21 - 40 ( 98 total )
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
ILUVIEN Greater China and Western Pacific Licensing Deal; Raising PT to $16
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Commercial Expansion Continues in Europe; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
4Q and Full-Year 2020 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
ILUVIEN Launched in Finland for DME and Uveitis; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Top- and Bottom-Line Beat in 3Q20; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
ILUVIEN European Expansion; NEW DAY Trial Starts Enrollment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
NEW DAY Trial May Change Retinal Disease Therapy Paradigm; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
New Study Assessing ILUVIEN as Baseline DME Therapy Initiated; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Preliminary 1Q20 Results Top-Line Beat; Reiterate Buy; Modulating PT to $14
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
4Q and Full-Year 2019 Results Show Solid Growth; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Additional Term Loan Secured With Revenue Milestone; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
ILUVIEN for the Treatment of Posterior Uveitis Approved in Benelux Countries; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Reverse Stock Split Effected; Reiterate Buy; Adjusting PT to $15
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
3Q19 Financial Results Reported; Reiterate Buy; Reducing PT to $1
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Preliminary Top-Line Revenue for 3Q19 Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Imminent Launch of ILUVIEN in Germany for Uveitis; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
2Q19 Results Disappoint Due to Sales Force Turnover; Reiterate Buy; Lowering PT to $1.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
UK NICE Issues Positive Coverage Decision in Posterior Uveitis; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y